Randomized Trialhigh evidence
Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.
The New England journal of medicine·August 28, 2026·PMID 42663312
Why it mattersNonobstructive HCM has substantial morbidity and no proven medical therapy. This trial provides the first evidence that a cardiac myosin inhibitor improves exercise capacity and symptoms in this population, addressing a major unmet need.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled